| Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors SA Moghadasi, E Heilmann, AM Khalil, C Nnabuife, FL Kearns, C Ye, ... Science Advances 9 (13), eade8778, 2023 | 124 | 2023 |
| SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376 E Heilmann, F Costacurta, SA Moghadasi, C Ye, M Pavan, D Bassani, ... Science translational medicine 15 (678), eabq7360, 2022 | 94 | 2022 |
| A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition E Heilmann, F Costacurta, S Geley, SA Mogadashi, A Volland, B Rupp, ... Communications Biology 5 (1), 391, 2022 | 16 | 2022 |
| SARS-CoV-2 3CLpro mutations confer resistance to Paxlovid (nirmatrelvir/ritonavir) in a VSV-based, non-gain-of-function system E Heilmann, F Costacurta, A Volland, D von Laer BioRxiv, 2022.07. 02.495455, 2022 | 13 | 2022 |
| SARS-CoV-2 3CL (pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376. Sci. Transl. Med. 15, eabq7360 E Heilmann, F Costacurta, SA Moghadasi, C Ye, M Pavan, D Bassani, ... | 8 | 2022 |
| Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. bio Rxiv: 2022.08. 07.503099 SA Moghadasi, E Heilmann, AM Khalil, C Nnabuife, FL Kearns, C Ye, ... There is no corresponding record for this reference, 2022 | 8 | 2022 |
| Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. bioRxiv (2022) SA Moghadasi, E Heilmann, A Khalil, C Nnabuife, FL Kearns, C Ye, ... Google Scholar, 0 | 5 | |
| A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system F Costacurta, A Dodaro, D Bante, H Schöppe, JY Peng, B Sprenger, X He, ... PLoS pathogens 20 (9), e1012522, 2024 | 4 | 2024 |
| Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir L Krismer, H Schöppe, S Rauch, D Bante, B Sprenger, A Naschberger, ... npj Viruses 2 (1), 23, 2024 | 1 | 2024 |
| Vesicular stomatitis virus as a platform for protease activity measurements S Rauch, F Costacurta, D von Laer, E Heilmann Current Protocols 4 (11), e70062, 2024 | | 2024 |
| Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system S Rauch, F Costacurta, H Schöppe, JY Peng, D Bante, EE Erisoez, ... Antiviral Research 231, 105969, 2024 | | 2024 |
